American Regent v. Xiromed: Selenium Injection Patent Consolidated Into 13-Defendant ANDA Battle
American Regent, Inc. filed suit against Xiromed, LLC and Xiromed Pharma España, S.L. in New Jersey District Court asserting US11998565B2, covering parenteral selenium injection formulations. The case was one of 13 parallel Hatch-Waxman actions filed simultaneously against generic manufacturers and was consolidated into a single lead proceeding within 128 days of filing.
Hatch-Waxman broadside: 13 generics, one selenium patent
American Regent, Inc., a specialty pharmaceutical company and holder of US11998565B2, filed thirteen parallel infringement actions in the District of New Jersey on July 16, 2024, targeting a broad field of generic manufacturers seeking to launch selenium injection products. The Xiromed action (2:24-cv-07811) named Xiromed, LLC and its Spanish affiliate Xiromed Pharma España, S.L. as defendants, asserting that their ANDA filings for selenium injection products — at concentrations including 60 mcg/mL and 12 mcg/2 mL — infringe the asserted patent.
On October 22, 2024, the court entered a consolidation order merging all thirteen actions into lead case No. 24-7791 against Accord Healthcare, Inc. The Xiromed docket was administratively closed as a standalone proceeding, with all future filings to be maintained under the lead caption. Consolidation is a procedural mechanism — it does not resolve the underlying infringement claims on the merits and does not constitute a dismissal or judgment for either party.
The 128-day path from filing to consolidation order is consistent with efficient docket management in multi-defendant ANDA cases, where courts routinely consolidate parallel actions to avoid duplicative discovery and inconsistent rulings. The substantive question — whether Xiromed’s selenium injection ANDA products infringe US11998565B2 — remains open and will be litigated in the consolidated proceeding. The breadth of the defendant roster, spanning U.S. subsidiaries and foreign parent entities across thirteen actions, suggests American Regent is pursuing an aggressive exclusivity-protection strategy ahead of any generic launch window.
Filing to Case Consolidated in 128 days
128 days to consolidation order — faster than median ANDA consolidation timelines
Case consolidated: what the order means for Xiromed and the broader litigation
Consolidation is procedural — no merits outcome
A consolidation order under Fed. R. Civ. P. 42(a) merges cases sharing common questions of law or fact into a single proceeding. It does not dismiss any claims, enter judgment, or resolve infringement. The Xiromed docket is administratively closed as a standalone case, but American Regent’s infringement claims against Xiromed survive fully and will be adjudicated in lead case No. 24-7791.
Rule 42(a) consolidationAmerican Regent retains all claims across all 13 defendants
Consolidation is neutral or mildly favourable for American Regent. Coordinated discovery and a single claim construction ruling across thirteen defendants reduces cost and eliminates the risk of inconsistent judgments. American Regent can pursue a unified infringement theory against all ANDA filers simultaneously, preserving the 30-month stay period that Hatch-Waxman litigation typically triggers.
Claims preservedXiromed faces consolidated litigation alongside 12 rivals
Xiromed must now defend within a multi-defendant consolidated action, which typically compresses individual negotiating leverage. Shared discovery may surface confidential ANDA details across competitors. However, consolidation also means Xiromed can benefit from invalidity and non-infringement arguments developed collectively — reducing per-defendant litigation cost relative to standalone proceedings.
Multi-defendant dynamicGeneric selenium launch window remains uncertain
With all thirteen ANDA defendants consolidated, the outcome of the lead proceeding will determine market access for multiple generic selenium injection products simultaneously. A finding of infringement with no invalidity escape would block launch for all consolidated defendants. Conversely, a single successful invalidity challenge could open the market for all. Stakeholders should monitor the lead docket (24-7791) for claim construction and summary judgment activity.
Launch timing at riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Specialty pharmaceutical company — holder of US11998565B2 covering selenium injection formulationsSearch in Eureka ↗ |
| Defendant | Xiromed, LLC | Company | Generic pharmaceutical company and Spanish affiliate seeking ANDA approval for selenium injectionsSearch in Eureka ↗ |
| Co-Defendant | Xiromed Pharma Espana, SL | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | JOHN C. LEDDY | Attorney | Counsel for Xiromed, LLCSearch in Eureka ↗ |
| Defendant law firm | Nutter, McClennen & Fish LLP | Law Firm | Representing Xiromed, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects standard multi-defendant ANDA case management rather than any merits determination. The court’s finding of ‘good cause’ to consolidate confirms that the thirteen actions share sufficiently common factual and legal questions — primarily the validity and infringement of US11998565B2 — to be tried together. No claims have been resolved. The Xiromed-specific docket closes procedurally, but infringement liability remains live in the lead proceeding. Practitioners should note that consolidation does not merge the cases for all purposes; separate judgments may still be entered per defendant.
US11998565B2 — Parenteral Selenium Injection Formulations
US11998565B2, filed under application number US18/124391, covers parenteral selenium injection formulations used in clinical nutrition and trace element supplementation. The products at issue span three concentration presentations: 600 mcg selenium per 10 mL, 60 mcg/mL, and 12 mcg per 2 mL — standard intravenous dosing formats for critically ill or nutritionally deficient patients. The patent’s grant and subsequent assertion against thirteen ANDA filers suggests American Regent is protecting a commercially significant formulation improvement over prior selenium injection art.
Selenium injections occupy a specialised but clinically essential segment of the parenteral nutrition market, used in ICU and long-term care settings. A patent of this type can establish durable market exclusivity if claim scope withstands challenge — making it a high-value asset for American Regent’s injectable portfolio. The breadth of the defendant roster, including major generic houses such as Sun Pharma, Dr. Reddy’s, Cipla, Hikma, and Zydus, indicates broad ANDA filing activity and signals that the generic market sees significant commercial opportunity in selenium injection products once exclusivity breaks.
Should you run an FTO against US11998565B2 for selenium injection products?
Any manufacturer, contract development organisation, or distributor developing or distributing parenteral selenium injection products — particularly at concentrations of 60 mcg/mL or adjacent formulations — should treat US11998565B2 as a live blocking patent until the consolidated litigation resolves. With thirteen ANDA defendants already named, American Regent has demonstrated willingness to assert broadly. Even formulations not identical to the named products may fall within claim scope depending on how the district court construes the claims.
PatSnap Eureka’s FTO Search Agent can map US11998565B2 claim language against your specific formulation parameters, flag prosecution history estoppel that may limit enforceability, and surface relevant prior art that may support an IPR petition or design-around strategy. Given the active consolidated litigation, real-time docket monitoring through PatSnap Litigation is also advisable to track claim construction orders and any inter partes review filings at the PTAB.
Run a freedom-to-operate analysis on US11998565B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases involving parenteral formulation patents
Explore parallel Hatch-Waxman infringement actions in New Jersey District Court involving injectable pharmaceutical formulation patents and multi-defendant ANDA consolidations.
What this case signals for the parenteral nutrition IP landscape
American Regent’s 13-front litigation campaign over selenium injections signals an aggressive Hatch-Waxman enforcement posture worth tracking closely.
Mass filing strategy signals strong confidence in US11998565B2
Filing thirteen parallel ANDA suits simultaneously is resource-intensive and typically reflects high patentee confidence in claim scope and validity. Generic manufacturers facing this playbook should prioritise early IPR petition analysis — inter partes review at the PTAB offers a faster, cheaper invalidity path than district court litigation and can shift settlement dynamics significantly.
Consolidation accelerates case pace — monitor the lead docket
With proceedings now unified under 24-7791, scheduling orders, claim construction briefing, and any dispositive motions will proceed on a single timeline. IP teams at competing generic manufacturers — including those not yet named — should track the lead docket for claim construction rulings that will effectively define the patent’s reach across all selenium injection ANDA products.
American v Xiromed — key questions answered
The case was consolidated with twelve parallel actions into lead case No. 24-7791 by court order dated October 22, 2024. No merits ruling was issued. American Regent’s infringement claims against Xiromed under US11998565B2 remain live and will be litigated in the consolidated proceeding.
US11998565B2 (application no. US18/124391) is the asserted patent. It covers parenteral selenium injection formulations. The products at issue are selenium injections at concentrations of 600 mcg/10 mL, 60 mcg/mL, and 12 mcg/2 mL — standard intravenous clinical nutrition presentations.
Consolidation under Fed. R. Civ. P. 42(a) merges the Xiromed action with twelve other ANDA cases into a single proceeding. Xiromed’s standalone docket is administratively closed, but all infringement claims against Xiromed survive. Future rulings on claim construction, invalidity, and infringement will be issued in the lead case and will bind Xiromed.
American Regent filed thirteen parallel Hatch-Waxman actions in the District of New Jersey against defendants including Xiromed, Accord Healthcare, Aspiro Pharma, Cipla, Dr. Reddy’s Laboratories, Eugia Pharma, Gland Pharma, Hikma, Long Grove Pharmaceuticals, RK Pharma, Somerset Therapeutics, Sun Pharmaceutical, and Zydus Pharmaceuticals. All thirteen are now consolidated under lead case No. 24-7791.
Yes. Inter partes review petitions at the PTAB can be filed concurrently with district court ANDA litigation. A successful IPR petition could result in claim cancellation, which would moot the district court infringement claims. The IPR petition window is generally one year from service of the complaint, making early filing analysis time-sensitive for Xiromed and other consolidated defendants.
PatSnap Eureka searches patents and litigation data to answer instantly.